Relation of the -514C/T polymorphism in the hepatic lipase gene to serum HDL and LDL cholesterol levels in postmenopausal women under hormone replacement therapy

Atherosclerosis

Volumn 162, Issue 1, 2002, Pages 17-21

  Yamakawa Kobayashi, Kimiko ^a   Somekawa, Yoshiaki ^c   Fujimura, Mitsuko ^a   Tomura, Shigeo ^b   Arinami, Tadao ^a   Hamaguchi, Hideo ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Hepatic lipase; Hormone replacement therapy; Menopause; Promoter polymorphism

Indexed keywords

APOLIPOPROTEIN A1; CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; ASSOCIATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENOTYPE; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ADULT; AGED; ALLELES; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; GENOTYPE; HUMANS; JAPAN; LIPASE; LIVER; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; TREATMENT OUTCOME; TRIGLYCERIDES; WOMEN'S HEALTH;

EID: 0036229772     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00675-X     Document Type: Article

References (38)

1. Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients
2. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol
3. Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene
4. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol
5. Three polymorphisms associated with low hepatic lipase activity are common in African Americans
6. Hepatic lipase activity is lower in African American men than in white American men: Effects of 5′ flanking polymorphism in the hepatic lipase gene (LIPC)
7. Hepatic lipase (LIPC) promoter polymorphism in men with coronary artery disease. Allele frequency and effects on hepatic lipase activity and plasma HDL-C concentrations
8. A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women
9. Hepatic lipase: New insights from genetic and metabolic studies
10. Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normolipidemic females
11. High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase
12. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol
13. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution
14. Hepatic lipase gene polymorphisms influence plasma HDL levels. Results from Finnish EARS participants
15. Association of the C-514T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profiles. The Framingham Offspring study
16. Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations
17. Genetic variations of the hepatic lipase gene in Korean patients with coronary artery disease
18. Effect of estrogen on post-heparin lipolytic activity. Selective decline in hepatic triglyceride lipase
19. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women
20. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate
21. Influence of age and menopause on serum lipids and lipoproteins in healthy women
22. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
23. Hormone replacement therapy and cardiovascular disease
24. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: A review
25. Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by ApoE genotype?
26. Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene
27. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge
28. Automated immunoturbidimetric analysis of six plasma apolipoproteins: Correlation with radial immunodiffusion assays
29. Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants
30. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
31. Multivariate genetic analysis of high density lipoprotein particles
32. Genetic and environmental influences on serum lipid levels in twins
33. Menopause and risk of cardiovascular disease
34. Influence of age and menopause on serum lipids and lipoproteins in healthy women
35. Relationship between apolipoprotein E polymorphism, menopausal symptoms, and serum lipids during hormone replacement therapy
36. Ionizing radiation and genetic risks. VI. Chronic multifactorial diseases: A review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus
37. Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility
38. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis